DOCSLIB.ORG

6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2019 6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects Almannai, Mohammed ; Felemban, Rana ; Saleh, Mohammed A ; Faqeih, Eissa A ; Alasmari, Ali ; AlHashem, Amal ; Mohamed, Sarar ; Sunbul, Rawda ; Al-Murshedi, Fathiya ; AlThihli, Khalid ; Eyaid, Wafaa ; Ali, Rehab ; Ben-Omran, Tawfeg ; Blau, Nenad ; El-Hattab, Ayman W ; Alfadhel, Majid Abstract: BACKGROUND: Tetrahydrobiopterin is an essential cofactor for the hydroxylation of aro- matic amino acids phenylalanine, tyrosine, and tryptophan. Therefore, tetrahydrobiopterin deficiency results in hyperphenylalaninemia as well as dopamine and serotonin depletion in the central nervous system. The enzyme 6-pyruvoyltetrahydropterin synthase catalyzes the second step of de novo synthesis of tetrahydrobiopterin, and its deficiency is the most frequent cause of tetrahydrobiopterin metabolism disorders. METHOD: We conducted a retrospective chart review of 28 subjects from 24 families with molecularly confirmed 6-pyruvoyltetrahydropterin synthase deficiency from six centers in three Arab countries. We reviewed clinical, biochemical, and molecular data. We also reviewed previously published cohorts of subjects with 6-pyruvoyltetrahydropterin synthase deficiency. RESULTS: Similar to previous observations, we show that early treatment (less than two months) is associated with better outcome. We identify eight PTS variants in 24 independent families. The most common variant is (c.238A>G; p.M80V) with an allele count of 33%. We also identify one novel variant (c.2T>G; p.?). CONCLUSION: The deficiency of 6-pyruvoyltetrahydropterin synthase is relatively common in the Arab population and should be considered in individuals with hyperphenylalaninemia. More natural history studies with com- prehensive biochemical and molecular genetics data are needed for a robust base for the development of future therapy. DOI: https://doi.org/10.1016/j.pediatrneurol.2019.02.008 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-180681 Journal Article Published Version The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. Originally published at: Almannai, Mohammed; Felemban, Rana; Saleh, Mohammed A; Faqeih, Eissa A; Alasmari, Ali; Al- Hashem, Amal; Mohamed, Sarar; Sunbul, Rawda; Al-Murshedi, Fathiya; AlThihli, Khalid; Eyaid, Wafaa; Ali, Rehab; Ben-Omran, Tawfeg; Blau, Nenad; El-Hattab, Ayman W; Alfadhel, Majid (2019). 6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects. Pediatric Neurology, 96:40-47. DOI: https://doi.org/10.1016/j.pediatrneurol.2019.02.008 2 Pediatric Neurology 96 (2019) 40e47 Contents lists available at ScienceDirect Pediatric Neurology journal homepage: www.elsevier.com/locate/pnu Original Article 6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects Mohammed Almannai, MD a, Rana Felemban, MD a, Mohammed A. Saleh, MD a, Eissa A. Faqeih, MD a, Ali Alasmari, MD a, Amal AlHashem, MD b, c, Sarar Mohamed, MD b, Rawda Sunbul, MD d, Fathiya Al-Murshedi, MD e, Khalid AlThihli, MD e, Wafaa Eyaid, MD f, Rehab Ali, MD g, Tawfeg Ben-Omran, MD g, Nenad Blau, MD, PhD h, i, * Ayman W. El-Hattab, MD j, k, Majid Alfadhel, MD f, l, m, a Section of Medical Genetics, Children's Hospital, King Fahad Medical City, Riyadh, Saudi Arabia b Department of Pediatric, Prince Sultan Medical Military City, Riyadh, Saudi Arabia c Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia d Pediatrics Medical Genetic Unit (PMGU), Pediatrics Department, Qatif Central Hospital, Qatif, Saudi Arabia e Department of Genetics, College of Medicine, Sultan Qaboos University, Muscat, Sultanate of Oman f Division of Genetics, Department of Pediatrics, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (MNGHA), Riyadh, Saudi Arabia g Clinical and Metabolic Genetics Section, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar h Dietmar-Hopp-Metabolic Center, University Children's Hospital, Heidelberg, Germany i Division of Metabolism, University Children's Hospital Zurich, Switzerland j Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates k Genetics Clinics, KidsHeart Medical Center, Dubai, United Arab Emirates l King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia m College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia article info abstract Article history: Background: Tetrahydrobiopterin is an essential cofactor for the hydroxylation of aromatic amino acids Received 18 September 2018 phenylalanine, tyrosine, and tryptophan. Therefore, tetrahydrobiopterin deficiency results in hyper- Accepted 10 February 2019 phenylalaninemia as well as dopamine and serotonin depletion in the central nervous system. The enzyme Available online 18 February 2019 6-pyruvoyltetrahydropterin synthase catalyzes the second step of de novo synthesis of tetrahydrobiopterin, and its deficiency is the most frequent cause of tetrahydrobiopterin metabolism disorders. Keywords: Method: We conducted a retrospective chart review of 28 subjects from 24 families with molecularly Phenylketonuria confirmed 6-pyruvoyltetrahydropterin synthase deficiency from six centers in three Arab countries. We Tetrahydrobiopterin PTPS deficiency reviewed clinical, biochemical, and molecular data. We also reviewed previously published cohorts of fi Inborn errors of metabolism subjects with 6-pyruvoyltetrahydropterin synthase de ciency. Results: Similar to previous observations, we show that early treatment (less than two months) is asso- ciated with better outcome. We identify eight PTS variants in 24 independent families. The most common variant is (c.238A>G; p.M80V) with an allele count of 33%. We also identify one novel variant (c.2T>G; p.?). Conclusion: The deficiency of 6-pyruvoyltetrahydropterin synthase is relatively common in the Arab population and should be considered in individuals with hyperphenylalaninemia. More natural history studies with comprehensive biochemical and molecular genetics data are needed for a robust base for the development of future therapy. © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Sciences; Division of Genetics; Department of Pediatrics; King Abdulaziz Medical Funding: No funding was associated with this study. City; Ministry of National Guard-Health Affairs (MNGHA); Riyadh, Saudi Arabia. Competing interests: The authors declare that they have no competing interests. E-mail address: [email protected] (M. Alfadhel). * Communications should be addressed to: Alfadhel; King Abdullah International Medical Research Center (KAIMRC); King Saud Bin Abdulaziz University for Health https://doi.org/10.1016/j.pediatrneurol.2019.02.008 0887-8994/© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). M. Almannai et al. / Pediatric Neurology 96 (2019) 40e47 41 Introduction In addition to its role in phenylalanine hydroxylation, BH4 is also an essential cofactor for tyrosine and tryptophan hydroxylases, Phenylketonuria (PKU; OMIM #261600), which was first re- which are rate-limiting enzymes in catecholamine and serotonin ported by Asbjorn€ Folling€ in 1934, is one of the most common biosyntheses, respectively. Therefore, besides HPA, BH4 deficiency inborn errors of metabolism with an estimated prevalence of 1 in also results in dopamine and serotonin depletion in the central 10,000 in the European population1. PKU was the first disorder for nervous system.8 This accounts for the progressive neurological which newborn screening was established through bacterial inhi- deterioration in that subset of individuals with HPA despite early bition assay by Robert Guthrie and Ada Susi in 1963.2 PKU is caused dietary management. Finally, BH4 is also an essential cofactor for by the deficiency of phenylalanine hydroxylase, which catalyzes the the three isoforms of nitric oxide synthase. hydroxylation of phenylalanine to generate tyrosine (Fig). As a Disorders of BH4 metabolism account for only 1% to 2% of pa- result, phenylalanine will accumulate to toxic levels causing irre- tients with HPA in Europeans,8 whereas they are more common in versible intellectual disability (ID). some other ethnic groups. For example, BH4 deficiency accounts for Hydroxylation of phenylalanine to tyrosine through phenylala- more than 10% of HPA patients in some countries in East Asia9,10 nine hydroxylase requires the essential cofactor tetrahy- reaching up to one-third of cases in some reports.11 In a cross- drobiopterin (BH4) that was first identified in the 1960s.3 More sectional study from Iran, 76 of 617 (12%) with HPA have BH4 de- than a decade later, a subgroup of individuals with PKU who ficiencies.12 In one old report from south Brazil, PTPS deficiency developed progressive neurological deterioration despite early di- alone represents 17% of cases with HPA.13 etary management was identified.4 The term malignant hyper- phenylalaninemia was then used to describe subjects who were Methods found to have deficiency in BH4,
Load more

Recommended publications
  • Guide for Hyperphenylalaninemia
    TM Guide For Hyperphenylalaninemia Laurie Bernstein, MS, RD, FADA Cindy Freehauf, RN, CGC Laurie Bernstein, MS, RD, FADA Fellow of the American Dietetic Association Assistant Professor- Department of Pediatrics Director, IMD Nutrition The Children's Hospital, Aurora CO Cindy Freehauf, RN, CGC Assistant Professor- Department of Pediatrics Clinical Coordinator, IMD Clinic The Children's Hospital, Aurora CO A special thank you to: Kathleen M. Martin, BS, BA for her enthusiasm for learning and excellent graphic skills. Intern, IMD Clinic The Children's Hospital, Aurora CO Second Edition Review Committee: Casey Burns, RD Janet A. Thomas, MD Metabolic Nutritionist Associate Professor, Pediatrics The Children's Hospital, Aurora CO Director, IMD Clinic The Children's Hospital, Aurora CO Sommer Myers, RD Metabolic Nutritionist Erica L. Wright, MS, CGC The Children's Hospital, Aurora CO Certified Genetic Counselor The Children's Hospital, Aurora CO Shannon L. Scrivner, MS, CGC Certified Genetic Counselor The Children's Hospital, Aurora CO Acknowledgments: Educational grant provided by Nutricia North America The Genetic Counseling Graduate Students of The University of Colorado at Denver and Health Sciences Center. TCH logo is a Licensed Trademark, all rights reserved. The Inherited Metabolic Clinic at The Children’s Hospital in Aurora, CO serves the Rocky Mountain Plains Region and at least 130 individuals with hyperphenylalaninemia (PKU). Children and families require a great deal of complex information, most often new and alien to their experience, in order to establish and maintain consistent and effective treatment. Our experience with the process of sharing such information with families motivated us develop this anticipatory guidance book with teaching aids.
    [Show full text]
  • Malignant Hyperphenylalaninemia Tetrahydrobiopterin (BH4) Phenylalanine
    Pediat. Res. 13: 1 150-1 155 (1979) Dihydropterine reductase (DHPR) phenylketonuria malignant hyperphenylalaninemia tetrahydrobiopterin (BH4) phenylalanine Malignant Hyperphenylalaninemia-Clinical Features, Biochemical Findings, and Experience with Administration of Biopterins D. M. DANKS, P. SCHLESINGER, F. FIRGAIRA, R. G. H. COTTON. B. M. WATSON, H. REMBOLD. AND G. HENNINGS Genetics Research Unit, Royal Children S Hospital Research Foundation, and Department of Paediatrics, Universi1.y of Melbourne, Parkville, Australia (D. M. D., P. S., F. F.. R. G. H. C., B. M. W.) and Max Planck Institutfur Biochemie. Germany (H. R., G. H.) Summary has been attributed to defective production of neurotransmitters derived from hydroxylation of tyrosine and of tryptophan (3, 4). Four cases of malignant hyperphenylalaninemia (MHPA) are The results of treatment with L-dopa and 5-hydroxytryptophan described. Pretreatment serum phenylalanine levels were 1.5, 3.0, support this contention (2, 3. 7). 2.4, and 0.9 mmoles/l. Dihydropteridine reductase (DHPR) defi- Four patients with MHPA seen in Melbourne since 1963 are ciency was proven in one patient by assays on cultured fibroblastic presented. One patient has been shown to have DHPR deficiency cells and was presumed in her sibling and in another deceased and her sister is presumed to have died of this defect. Both parents patient whose parents' fibroblastic cells show approximately 50% of another baby had DHPR levels in the heterozygote range of normal enzyme activity. DHPR and phenylalanine hydroxylase suggesting DHPR deficiency as the cause of her death. The 4th deficiency were excluded by assays on liver obtained at autopsy in baby had neither PH or DHPR deficiency and defective BH4 the 4th patient.
    [Show full text]
  • Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia
    003 1-399819113005-0435$03.00/0 PEDIATRIC RESEARCH Vol. 30, No. 5, 1991 Copyright 0 199 1 International Pediatric Research Foundation, Inc. Pr~ntc.d in U.S. A Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia ALBERT0 PONZONE, ORNELLA GUARDAMAGNA, SILVIO FERRARIS, GIOVANNI B. FERRERO, IRMA DIANZANI, AND RICHARD G. H. COTTON InstiflifeofPediatric Clinic(A.P., O.G., S.F., G.B.F., I.D.], University of Torino, 10126 Torino, Italy and Olive Miller Laboratory [R.G.H.C.],Murdoch Institute, Royal Children's Hospital, Vicroria,Australia 3052 ABSTRACT. Some cases of primary hyperphenylalanine- PKU to describe some cases clinically unresponsive to a Phe- mia are not caused by the lack of phenylalanine hydroxyl- restricted diet and later shown to be due to BH4 deficiency ase, but by the lack of its cofactor tetrahydrobiopterin. ( 1-4). These patients are not clinically responsive to a phenylal- By analyzing all the essential components of the complex anine-restricted diet, but need specific substitution therapy. hydroxylation system of aromatic amino acids, it became appar- Thus, it became necessary to examine all newborns ent that a defect in the BH4 recycling enzyme DHPR (EC screened as positive with the Guthrie test for tetrahydro- 1.66.99.7) and two defects in BH4 synthetic pathway enzymes, biopterin deficiency. Methods based on urinary pterin or guanosine triphosphate cyclohydrolase I (EC 3.5.4.16) and 6- on specific enzyme activity measurements are limited in PPH4S, may lead to cofactor deficiency resulting in HPA and in their availability, and the simplest method, based on the impaired production of dopamine and serotonin (5-7).
    [Show full text]
  • Relevance to Neurological Damage
    Postgrad Med J: first published as 10.1136/pgmj.62.724.113 on 1 February 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 113-123 Pteridines and mono-amines: relevance to neurological damage I. Smith, D.W. Howells and K. Hyland Institute ofChildHealth (University ofLondon), 30 Guilford Street, London WCIN2NR, UK. Summary: Patients with phenylalanine hydroxylase deficiency show increased concentrations of biopterins and neopterins, and reduced concentrations ofserotonin and catecholamines, when phenylalan- ine concentrations are raised. The pterin rise reflects increased synthesis of dihydroneopterin and tetrahydrobiopterin, and the amine fall a reduction in amine synthesis due to inhibition by phenylalanine of tyrosine and typtophan transport into neurones. The pterin and amine changes appear to be independent of each other and are present in the central nervous system as well as the periphery; they disappear when phenylalanine concentrations are reduced to normal. Patients with arginase deficiency show a similar amine disturbance but have normal pterin levels. The amine changes probably contribute neurological symptoms but pterin disturbance is not known to affect brain function. Patients with defective biopterin metabolism exhibit severely impaired amine synthesis due to tetrahydrobiopterin deficiency. Pterin concentrations vary with the site of the defect. Symptoms include profound hypokiesis and other features of basal ganglia disease. Neither symptoms nor amine changes are relieved by controlling phenylalanine concentrations. Patients with dihydropteridine reductase (DHPR) deficiency accumulate dihydrobiopterins and develop secondary folate deficiency which resembles that occurring in patients with defective 5,10-methylene tetrahydrofolate reductase activity. The latter disorder is also associated writh Parkinsonisn and defective amine and pterin turnover in the and a occurs in In central nervous system, demyelinating illness both disorders.
    [Show full text]
  • Different Strategies in the Treatment of Dihydropteridine Reductase Deficiency
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 1996 Different Strategies In the Treatment of Dihydropteridine Reductase Deficiency Spada, M ; Blau, N ; Meli, C ; Ferrero, G B ; de Sanctis, L ; Ferraris, S ; Ponzone, A DOI: https://doi.org/10.1515/pteridines.1996.7.3.107 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-155067 Journal Article Published Version Originally published at: Spada, M; Blau, N; Meli, C; Ferrero, G B; de Sanctis, L; Ferraris, S; Ponzone, A (1996). Different Strategies In the Treatment of Dihydropteridine Reductase Deficiency. Pteridines, 7(3):107-109. DOI: https://doi.org/10.1515/pteridines.1996.7.3.107 Spada et al.: Treatment of DHPR deficiency Pteridines Vol. 7, 1996, pp. 107 - 109 Different Strategies In the Treatment of Dihydropteridine Reductase Deficiency 2 l M . Spada', N. Blau , C. Meli\ G . B. rerrero', L. de Sanctis\ S. Ferraris and A. Ponzone'· 4§ IDipartimento di Scienze Pediatriche e dell'Adolcscenza, Universita'degli Studi di Torino, Italy 2Division of Clinical Chemistry, University Children's Hospital, Zurich, Switzerland 3 C linica Pediatrica, Universita'di Catania, Italy 4Facolta'di Magistero, Universita'di Messina, Italy (Received July IS, 1996) Introduction mal serum Phe levels. Despite substantial amounts of peripherally ad- Inherited deficiency of dihydropteridine reduc- ministered BH4 can be found in cerebrospinal tase (DHPR, EC 1.66.99.7) impairs the re- fluid (CSr), only some patients respond at the generation of tetrahydrobiopterin (BH 4), the es- central level to BH4 monotherapy (3,4).
    [Show full text]
  • Massive Parallel Sequencing As a New Diagnostic Approach For
    Chaiyasap et al. BMC Medical Genetics (2017) 18:102 DOI 10.1186/s12881-017-0464-x RESEARCH ARTICLE Open Access Massive parallel sequencing as a new diagnostic approach for phenylketonuria and tetrahydrobiopterin-deficiency in Thailand Pongsathorn Chaiyasap1, Chupong Ittiwut1,2, Chalurmpon Srichomthong1,2, Apiruk Sangsin3, Kanya Suphapeetiporn1,2,4* and Vorasuk Shotelersuk1,2 Abstract Background: Hyperphenylalaninemia (HPA) can be classified into phenylketonuria (PKU) which is caused by mutations in the phenylalanine hydroxylase (PAH) gene, and BH4 deficiency caused by alterations in genes involved in tetrahydrobiopterin (BH4) biosynthesis pathway. Dietary restriction of phenylalanine is considered to be the main treatment of PKU to prevent irreversible intellectual disability. However, the same dietary intervention in BH4 deficiency patients is not as effective, as BH4 is also a cofactor in many neurotransmitter syntheses. Method: We utilized next generation sequencing (NGS) technique to investigate four unrelated Thai patients with hyperphenylalaninemia. Result: We successfully identified all eight mutant alleles in PKU or BH4-deficiency associated genes including three novel mutations, one in PAH and two in PTS, thus giving a definite diagnosis to these patients. Appropriate management can then be provided. Conclusion: This study identified three novel mutations in either the PAH or PTS gene and supported the use of NGS as an alternative molecular genetic approach for definite diagnosis of hyperphenylalaninemia, thus leading to proper management of these patients in Thailand. Keywords: Next generation sequencing, Exome, Hyperphenylalaninemia, Phenylketonuria, Tetrahydrobiopterin deficiency, Newborn screening Background 120 μmol/l (2 mg/dl), the individual is considered to be Phenylketonuria (PKU) is an autosomal recessive metabolic hyperphenylalaninemia (HPA) and needs further diagnosis disorder, characterized by progressive intellectual disability, [4].
    [Show full text]
  • Blueprint Genetics Hyperphenylalaninemia Panel
    Hyperphenylalaninemia Panel Test code: ME2001 Is a 6 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hyperphenylalaninaemias including hyperphenylalaninemia due to BH4 deficiency. The genes on this panel are included in the Comprehansive Metabolism Panel. About Hyperphenylalaninemia Hyperphenylalaninemias (HPA) are errors in metabolism resulting in characterics of elevated levels of phenylalanine amino acid in the blood. Phenylketonuria (PKU) results in hyperphenylalaninemia if left untreated. Elevated levels if phenylalanine will make a severe risk of intellectual disability for a child. Unborn babies with mutation in homozygous state are unaffected as mother’s circulation prevents buildup. After birth, phenylalanine-restricted diet prevents intellectual problems and the persons with homozygous mutated genotype have normal mental development. However, maternal PKU without metabolic control predisposes babies to severe mental retardation and heart defects. This is an example of a genetic disease of a baby based on mother’s genotype. Classical PKU is caused by mutations in PAH, but some 2% of all HPAs result from impaired synthesis or recycling of tetrahydrobiopterin (BH4). Causative mutations in these cases are in GCH1, PCBD1, PTS or QDPR genes. The worldwide prevalence of PKU is estimated at 1:10 000 births having, however, rather big variation in different populations. The prevalence of tetrahydrobiopterin is estimated at <1:500 000 newborns. However, in certain populations
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Gene Transfer As a Potential Treatment for Tetralujdrobiopterin Deficient States
    Gene Transfer as a Potential Treatment for Tetralujdrobiopterin Deficient States Rickard F oxton Division of Neurochemistry Department of Molecular Neuroscience Institute of Neurology University College London Submitted November 2006 Funded by Brain Research Trust Thesis submitted for the degree of Doctor of Philosophy, University of London. I, Richard Hartas Foxton, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' 1 UMI Number: U592813 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U592813 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Tetrahydrobiopterin (BH4) is an essential cofactor for dopamine (DA), noradrenaline (NA), serotonin and nitric oxide (NO) synthesis in the brain. Inborn errors of BH4 metabolism including GTP cyclohydrolase 1 (GTP-CH) deficiency are debilitating diseases in which BH4, DA, 5-HT and NO metabolism are impaired. Current treatment for these disorders is typically monoamine replacement +/- BH4. Whilst correction of the primary defect is the ideal, BH4 treatment is problematic as it is expensive and inefficacious.
    [Show full text]
  • Isolation and Expression of Rat Liver Sepiapterin Reductase Cdna
    Proc. Nat!. Acad. Sci. USA Vol. 87, pp. 6436-6440, August 1990 Genetics Isolation and expression of rat liver sepiapterin reductase cDNA (tetrahydrobiopterin/biopterin/pyruvoyltetrahydropterin/aromatic amino acid hydroxylase/molecular cloning) BRUCE A. CITRON*, SHELDON MILSTIEN*, JOANNE C. GUTIERREZt, ROBERT A. LEVINE, BRENDA L. YANAK*§, AND SEYMOUR KAUFMAN*¶ *Laboratory of Neurochemistry, Room 3D30, Building 36, and tLaboratory of Cell Biology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; and tLaboratory of Molecular Neurobiology, Lafayette Clinic, 951 East Lafayette, Detroit, MI 48207 Contributed by Seymour Kaufman, June 7, 1990 ABSTRACT Sepiapterin reductase (7,8-dihydrobiopterin: either case, the final carbonyl reduction to form tetrahydro- NADP+ oxidoreductase, EC 1.1.1.153) catalyzes the terminal biopterin must be catalyzed by sepiapterin reductase. step in the biosynthetic pathway for tetrahydrobiopterin, the In the present study, we have screened a rat liver cDNA cofactor necessary for aromatic amino acid hydroxylation. We library with a specific antibody that reacts positively to the report here the isolation of a cDNA clone for rat liver sepia- enzyme band on Western blots (19). These clones were used pterin reductase. The cDNA has been excised from a lambda to further characterize the enzyme and to begin to elucidate vector and the DNA sequence was determined. The insert the functional sites ofthe enzymes in the tetrahydrobiopterin contains the coding sequence for at least 95% of the rat enzyme biosynthetic pathway. 11 and is fused to the Escherichia coli (3-galactosidase N-terminal segment and the lac promoter. The N-terminal region of the clone contains an extraordinarily high G+C content.
    [Show full text]
  • Biosynthesis of Tetrahydrobiopterin in Man
    J. tnher. Metab. Dis. 8 Suppl. 1 (I985) 28-33 Biosynthesis of Tetrahydrobiopterin in Man H.-CH. CURTIUS, D. HEINTEL, S. GHISLA1, TH. KUSTER, W. LEIMBACHER and A. NIEDERWIESER Division of Clinical Chemistry, Department of Pediatrics, University of Zurich, Switzerland t Department of Biology, University of Constance, POB 5560, D-7750 Constance, FRG The biosynthesis oftetrahydrobiopterin (BH4) from dihydroneopterin triphosphate (NHzP3) was studied in human liver extract. The phosphate-eliminating enzyme (PEE) was purified ~ 750-fold. The conversion of NH2P3 to BH~ was catalyzed by this enzyme in the presence of partially purified sepiapterin reductase, Mg z ÷ and NADPH. The PEE is heat stable when heated at 80 °C for 5 min. It has a molecular weight of 63 000 daltons. One possible intermediate 6-(l'-hydroxy-2'-oxopropyl)5,6,7,8-tetrahydropterin(2'-oxo-tetrahydro- pterin) was formed upon incubation of BH4 in the presence of sepiapterin reductase and NADP ÷ at pH 9.0. Reduction of this compound with NaBD4 yielded monodeutero threo and erythro-BH4, the deuterium was incorporated at the 2' position. This and the UV spectra were consistent with a 2'-oxo-tetrahydropterin structure. Dihydrofolate reductase (DHFR) catalyzed the reduction of BH2 to BH4 and was found to be specific for the pro-R-NADPH side. The sepiapterin reductase catalyzed the transfer of the pro-S hydrogen of NADPH during the reduction of sepiapterin to BHa. In the presence of crude liver extracts the conversion of NHzP3 to BH4 requires NADPH. Two deuterium atoms were incorporated from (4S-2H)NADHP in the 1' and 2' position of the BH4 side chain.
    [Show full text]
  • Natalis Information Sheet V03
    Sema4 Natalis Clinical significance of panel Sema4 has designed and validated Natalis, a supplemental newborn screening panel offered for newborns, infants, and young children. This test may be offered to parents as an addition to the state mandated newborn screening that their child received at birth. This panel includes next-generation sequencing, targeting genotyping, and multiplex ligation-dependent probe amplification in a total of 166 genes to screen for 193 conditions that have onset in infancy or early childhood and for which there is treatment or medical management that, when administered early in an infant or child’s life, will significantly improve the clinical outcome. Conditions included in this panel were curated based on criteria such as: inclusion on current state mandated newborn screening panels, onset of symptoms occurring <10 years of age, evidence of high penetrance (>80%), and availability of a treatment or improvement in life due to early intervention. Sema4 has also designed and validated a pediatric pharmacogenetic (PGx) genotyping panel as an adjunct test to the Natalis assay. This panel includes 10 genes and 41 sequence variants involved in drug response variability. The genes and variants in the PGx genotyping panel inform on more than 40 medications that can be prescribed during childhood. Currently, there is evidence supporting the clinical utility of testing for certain PGx variants for which there are genotype-directed clinical practice recommendations for selected gene/drug pairs. Approximately 95% of all individuals will carry at least one clinically actionable variant in the PGx panel. Testing methods, sensitivity, and limitations A cheek swab, saliva sample, or blood sample is provided by the child and a biological parent.
    [Show full text]